As a new development, the effectiveness of ICI as neoadjuvant chemotherapy is being further explored, and the therapeutic effect of the combination therapy of molecular targeted drugs and ICI for HER2-positive gastric cancer is attracting attention. This evidence concerns the gene ERBB2 and gastric cancer.